- Home
- Automated
- List of product information
- BOOSTRIX POLIO SUSPENSION FOR INJECTION [SIN15888P]
BOOSTRIX POLIO SUSPENSION FOR INJECTION [SIN15888P]
Active ingredients: BOOSTRIX POLIO SUSPENSION FOR INJECTION
Last updated 26 October 2025
On this page
Product Info
BOOSTRIX POLIO SUSPENSION FOR INJECTION
[SIN15888P]
Product information
Active Ingredient and Strength | DIPHTHERIA TOXOID - 2.5 LF/0.5 ML - NOT LESS THAN 2 INTERNATIONAL UNITS |
Dosage Form | INJECTION, SUSPENSION |
Manufacturer and Country | GLAXOSMITHKLINE BIOLOGICALS SAS - FRANCE |
Registration Number | SIN15888P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07CA02 |
Indications
Boostrix Polio is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of three years onwards (see Posology).
The use of Boostrix Polio should be in accordance with official recommendations.
Dosage and Administration
Posology
A single 0.5 ml dose of the vaccine is recommended.
Boostrix Polio may be administered from the age of three years onwards. Boostrix Polio should be administered in accordance with official recommendations and/or local practice regarding the use of vaccines with reduced content of diphtheria toxoid plus tetanus toxoid in combination with pertussis and poliomyelitis antigens.
Boostrix Polio can be administered to pregnant women during the second or the third trimester in accordance with official recommendations (see Pregnancy and Pharmacodynamics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Boostrix Polio may also be administered to adolescents and adults with unknown vaccination status or incomplete vaccination against diphtheria, tetanus and pertussis as part of an immunisation series against diphtheria, tetanus, pertussis and polio (see Pharmacodynamics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Based on data in adults, two additional doses of a diphtheria and tetanus containing vaccine are recommended one and six months after the first dose to maximize the vaccine response against diphtheria and tetanus.
Boostrix Polio can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.
Repeat vaccination against diphtheria, tetanus, pertussis and poliomyelitis should be performed at intervals as per official recommendations (generally 10 years).
Method of administration
Boostrix Polio is for deep intramuscular injection, preferably in the deltoid region (see also Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
Boostrix Polio should not be administered to subjects with known hypersensitivity to any component of the vaccine (see Quantitative and Qualitative composition and List of Excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis or poliomyelitis vaccines.
Boostrix Polio is contraindicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus and poliomyelitis vaccines.
Boostrix Polio should not be administered to subjects who have experienced neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes, see Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).